POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (5.13.2021, 12:396pm CEST, WHO):   U.S. 36,412    India 362,727    Brazil 72,715    France 18,323    Turkey 14,497    Russia 8,115    The United Kingdom 2,474    Italy 6,943    Spain 2,768    Germany 14,909    Argentina 25,976    Columbia 16,425    Poland 4,159    Iran 16,409    Mexico 1,897    Ukraine 4,538    Peru 4,869    Indonesia 4,608    Czechia 1,686    South Africa 2,759    The Netherlands 5,586    Canada 5,386    Chile 3,902    Iraq 4,666    Philippines 4,812    Romania 1,156    Sweden 2,463    Pakistan 2,881    Bangladesh 1,140    Serbia 1,125    Japan 6,927    United Arab Emirates 1,508    Malaysia 4,765    Saudi Arabia 1,020    Nepal 9,238    Greece 3,172    Croatia 1,471    Georgia 1,409    Tunisia 1,105    Bolivia 2,369    Paraguay 2,377    Costa Rica 2,236    Lithuania 1,266    Egypt 1,187    Guatemala 1,416    Uruguay 2,977    Honduras 1,130    Bahrain 1,539    Sri Lanka 1,429    Cuba 1,207    Thailand 14,887    Maldives 1,572    China 32    Singapore 16    New Zealand 1    Australia 8    South Korea 715   

After 60 years new drug for lupus from Canada approved in U.S.

Christian Fernsby |
People living with lupus will soon have access to a breakthrough treatment discovered by an Albertan life sciences entrepreneur, who is creating a more globally competitive drug commercialization industry in Canada.

Article continues below




Dr. Robert Foster, an adjunct professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, discovered voclosporin in the early 1990s after founding a start-up drug company in his Edmonton basement.

It would take nearly 30 years, but the drug would earn the approval of the U.S. Food and Drug Administration to treat lupus-related kidney disease. Voclosporin was approved by the FDA earlier this year.

"This is a homegrown Canadian success story. The FDA doesn't approve Canadian drugs often," Foster said. " Voclosporin will improve people's lives; it's a breakthrough for people living with lupus."

Medical treatments for lupus are rare. Volcosporin is only the second treatment to come to market to treat lupus in more than 60 years. It is not yet approved for use in Canada. While Foster understands possible frustration from Canadians unable to access the new lupus therapy, he expressed hope and optimism for the future of Canada's life sciences sector.

Since developing voclosporin, Foster has become CEO of Hepion Pharmaceuticals - a US company with its research and development headquartered in Edmonton. Hepion is now researching a treatment for fatty liver disease, and has joined forces with Alberta's leading drug commercialization accelerator - Applied Pharmaceutical Innovation (API).


What to read next

Rich, poor have huge mortality gap in U.S.: 14.6 years
Global life expectancy on rise, major inequalities persist
Washing hands - a good investment in your health